Document is current
Any future updates will be listed below
-
Authors
Petridis, Petros D. https://orcid.org/0000-0001-7608-5723
Grinband, Jack
Agin-Liebes, Gabrielle
Kinslow, Connor J.
Zeifman, Richard J.
Bogenschutz, Michael P. https://orcid.org/0000-0003-4530-3470
Griffiths, Roland R.
Ross, Stephen
-
Funding
Funding for this research was provided by:
Usona Institute Scholarship
U.S. Department of Health & Human Services | National Institutes of Health (T32DA007250, UL1 TR000038)
Canadian Institutes of Health Research
Heffter Research Institute
Riverstyx Foundation William Linton Betsy Gordon Foundation McCormick Family Fetzer Institute George Goldsmith Ekaterina Malievskaia
RiverStyx Foundation NYU Clinical and Translational Science Institute Carey and Claudia Turnbull William Linton Robert Barnhart Arthur Altschul Kelly Fitzsimmons George Goldsmith Ekaterina Malievskaia
- License Information
-
More Information
Article History
Received: 18 March 2024
Accepted: 17 September 2024
First Online: 7 October 2024
Competing interests
: R.J.Z. is a post-doctoral fellow in the NYU Langone Psychedelic Medicine Research Training program funded by MindMed. M.P.B. is principal investigator of the NYU Langone Center for Psychedelic Medicine Research Training Program, funded by MindMed. M.P.B. has received research funding from Tilray Canada, the Multidisciplinary Association for Psychedelic Studies (MAPS) PBC, B.More Inc., the Heffter Research Institute, the Turnbull Family Foundation, the Fournier Family Foundation, Dr. Bronner’s Family Foundation, Bill Linton and the Riverstyx Foundation. M.P.B. serves on the Advisory Board of Ajna Labs LLC, Journey Colab and Bright Minds Biosciences, Inc. He is named as inventor on patent applications relating to the use of psilocybin for alcohol use disorder but has waived all rights and has no prospect of financial benefit. S.R. is the Director of NYU Langone Center for Psychedelic Medicine Research Training Program, which is funded by MindMed. S.R. currently receives, or has received in the past 36 months, grant support for clinical research from the National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), Heffter Research Institute, Usona Institute, Council on Spiritual Practices (CSP), Multidisciplinary Association of Psychedelic Studies (MAPS) and Reset Pharmaceuticals. S.R. is listed as a coinventor in two provisional patent applications (N420838US and N419987US) related to the use of psilocybin to treat psychiatric and existential distress in cancer. These provisional patent applications were filed by New York University Grossman School of Medicine and licensed by Reset Pharmaceuticals. S.R. has waived all rights in relation to these provisional patent applications and has no prospect of financial gain related to any future commercialization efforts related to these patents. The other authors declare no competing interests.
